Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas

Abstract Adenosquamous carcinoma of the pancreas (ASCP) is a rare histological subtype of pancreatic cancer with a poor prognosis and a high metastasis rate. However, little is known about its genomic landscape and prognostic biomarkers. A total of 48 ASCP specimens and 98 pancreatic ductal adenocar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Precision clinical medicine 2023-12, Vol.6 (4), p.pbad030-pbad030
Hauptverfasser: Jiang, Yina, Wu, Yinying, Zhang, Liwen, Wang, Yan, Xu, Guiping, Deng, Yuan, Han, Liang, Li, Enxiao, Ma, Qingyong, Xu, Mian, Wu, Zheng, Wang, Zheng
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page pbad030
container_issue 4
container_start_page pbad030
container_title Precision clinical medicine
container_volume 6
creator Jiang, Yina
Wu, Yinying
Zhang, Liwen
Wang, Yan
Xu, Guiping
Deng, Yuan
Han, Liang
Li, Enxiao
Ma, Qingyong
Xu, Mian
Wu, Zheng
Wang, Zheng
description Abstract Adenosquamous carcinoma of the pancreas (ASCP) is a rare histological subtype of pancreatic cancer with a poor prognosis and a high metastasis rate. However, little is known about its genomic landscape and prognostic biomarkers. A total of 48 ASCP specimens and 98 pancreatic ductal adenocarcinoma (PDAC) tumour specimens were sequenced to explore the genomic landscape and prognostic biomarkers. The homozygous deletion of the 9p21.3 region (including CDKN2A, CDKN2B, and MTAP) (9p21 loss) occurred in both ASCP and PDAC, and a higher frequency of 9p21 loss was observed in ASCP (12.5% vs 2.0%, P = 0.022). Notably, 9p21 loss was significantly associated with poor disease-free survival (DFS) in ASCP patients (mDFS (Median DFS) = 4.17 vs 7.33 months, HR (Hazard Ratio) = 3.70, P = 0.009). The most common gene alterations in patients with ASCP were KRAS (96%), TP53 (81%), CDKN2A (42%), SMAD4 (21%), CDKN2B (13%), and FAT3 (13%). The mutation rates of ACVR2A (6.25% vs 0%), FANCA (6.25% vs 0%), RBM10 (6.25% vs 0%), and SPTA1 (8.33% vs 1.02%) were significantly higher in ASCP than in PDAC. In conclusion, we have comprehensively described the genomic landscape of the largest cohort of ASCP patients to date and highlight that 9p21 loss may be a promising prognostic biomarker for ASCP, which provides a molecular basis for prognosis prediction and new therapeutic strategies for ASCP.
doi_str_mv 10.1093/pcmedi/pbad030
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2895709371</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/pcmedi/pbad030</oup_id><sourcerecordid>2895709371</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-f4ffafb717606da3a84990b8029eff137df563ab731ca86762f5e5d3da170df03</originalsourceid><addsrcrecordid>eNqFkD1PwzAURS0EElXpyuwRhrTPcRInI6qAIlVigTl68Qc1amLXToT497hKd6Z3h3Ovng4h9wzWDBq-8bLXym58hwo4XJFFXrIqY6Vg1ylDU2UlB35LVjF-A0DOiqKoYUHM3sVInaHyEFzvous1bXzOqI0UY3TS4qgV_bHjgSL1zgXqg_saXEyAHSgqnfJpwt5NkUoM0g6ux_PieNDU4yCDxnhHbgweo15d7pJ8vjx_bHfZ_v31bfu0z2TB-JiZwhg0nWCigkohx7poGuhqyBttDONCmbLi2AnOJNaVqHJT6lJxhUyAMsCX5GHeTU-eJh3HtrdR6uMRB50ebPO6KUXyJVhC1zMqQ1IQtGl9sD2G35ZBe3bazk7bi9NUeJwLbvL_sX-mOnuP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2895709371</pqid></control><display><type>article</type><title>Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Oxford University Press (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Jiang, Yina ; Wu, Yinying ; Zhang, Liwen ; Wang, Yan ; Xu, Guiping ; Deng, Yuan ; Han, Liang ; Li, Enxiao ; Ma, Qingyong ; Xu, Mian ; Wu, Zheng ; Wang, Zheng</creator><creatorcontrib>Jiang, Yina ; Wu, Yinying ; Zhang, Liwen ; Wang, Yan ; Xu, Guiping ; Deng, Yuan ; Han, Liang ; Li, Enxiao ; Ma, Qingyong ; Xu, Mian ; Wu, Zheng ; Wang, Zheng</creatorcontrib><description>Abstract Adenosquamous carcinoma of the pancreas (ASCP) is a rare histological subtype of pancreatic cancer with a poor prognosis and a high metastasis rate. However, little is known about its genomic landscape and prognostic biomarkers. A total of 48 ASCP specimens and 98 pancreatic ductal adenocarcinoma (PDAC) tumour specimens were sequenced to explore the genomic landscape and prognostic biomarkers. The homozygous deletion of the 9p21.3 region (including CDKN2A, CDKN2B, and MTAP) (9p21 loss) occurred in both ASCP and PDAC, and a higher frequency of 9p21 loss was observed in ASCP (12.5% vs 2.0%, P = 0.022). Notably, 9p21 loss was significantly associated with poor disease-free survival (DFS) in ASCP patients (mDFS (Median DFS) = 4.17 vs 7.33 months, HR (Hazard Ratio) = 3.70, P = 0.009). The most common gene alterations in patients with ASCP were KRAS (96%), TP53 (81%), CDKN2A (42%), SMAD4 (21%), CDKN2B (13%), and FAT3 (13%). The mutation rates of ACVR2A (6.25% vs 0%), FANCA (6.25% vs 0%), RBM10 (6.25% vs 0%), and SPTA1 (8.33% vs 1.02%) were significantly higher in ASCP than in PDAC. In conclusion, we have comprehensively described the genomic landscape of the largest cohort of ASCP patients to date and highlight that 9p21 loss may be a promising prognostic biomarker for ASCP, which provides a molecular basis for prognosis prediction and new therapeutic strategies for ASCP.</description><identifier>ISSN: 2096-5303</identifier><identifier>EISSN: 2516-1571</identifier><identifier>DOI: 10.1093/pcmedi/pbad030</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Precision clinical medicine, 2023-12, Vol.6 (4), p.pbad030-pbad030</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the West China School of Medicine &amp; West China Hospital of Sichuan University. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-f4ffafb717606da3a84990b8029eff137df563ab731ca86762f5e5d3da170df03</citedby><cites>FETCH-LOGICAL-c413t-f4ffafb717606da3a84990b8029eff137df563ab731ca86762f5e5d3da170df03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,1604,27924,27925</link.rule.ids></links><search><creatorcontrib>Jiang, Yina</creatorcontrib><creatorcontrib>Wu, Yinying</creatorcontrib><creatorcontrib>Zhang, Liwen</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Xu, Guiping</creatorcontrib><creatorcontrib>Deng, Yuan</creatorcontrib><creatorcontrib>Han, Liang</creatorcontrib><creatorcontrib>Li, Enxiao</creatorcontrib><creatorcontrib>Ma, Qingyong</creatorcontrib><creatorcontrib>Xu, Mian</creatorcontrib><creatorcontrib>Wu, Zheng</creatorcontrib><creatorcontrib>Wang, Zheng</creatorcontrib><title>Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas</title><title>Precision clinical medicine</title><description>Abstract Adenosquamous carcinoma of the pancreas (ASCP) is a rare histological subtype of pancreatic cancer with a poor prognosis and a high metastasis rate. However, little is known about its genomic landscape and prognostic biomarkers. A total of 48 ASCP specimens and 98 pancreatic ductal adenocarcinoma (PDAC) tumour specimens were sequenced to explore the genomic landscape and prognostic biomarkers. The homozygous deletion of the 9p21.3 region (including CDKN2A, CDKN2B, and MTAP) (9p21 loss) occurred in both ASCP and PDAC, and a higher frequency of 9p21 loss was observed in ASCP (12.5% vs 2.0%, P = 0.022). Notably, 9p21 loss was significantly associated with poor disease-free survival (DFS) in ASCP patients (mDFS (Median DFS) = 4.17 vs 7.33 months, HR (Hazard Ratio) = 3.70, P = 0.009). The most common gene alterations in patients with ASCP were KRAS (96%), TP53 (81%), CDKN2A (42%), SMAD4 (21%), CDKN2B (13%), and FAT3 (13%). The mutation rates of ACVR2A (6.25% vs 0%), FANCA (6.25% vs 0%), RBM10 (6.25% vs 0%), and SPTA1 (8.33% vs 1.02%) were significantly higher in ASCP than in PDAC. In conclusion, we have comprehensively described the genomic landscape of the largest cohort of ASCP patients to date and highlight that 9p21 loss may be a promising prognostic biomarker for ASCP, which provides a molecular basis for prognosis prediction and new therapeutic strategies for ASCP.</description><issn>2096-5303</issn><issn>2516-1571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqFkD1PwzAURS0EElXpyuwRhrTPcRInI6qAIlVigTl68Qc1amLXToT497hKd6Z3h3Ovng4h9wzWDBq-8bLXym58hwo4XJFFXrIqY6Vg1ylDU2UlB35LVjF-A0DOiqKoYUHM3sVInaHyEFzvous1bXzOqI0UY3TS4qgV_bHjgSL1zgXqg_saXEyAHSgqnfJpwt5NkUoM0g6ux_PieNDU4yCDxnhHbgweo15d7pJ8vjx_bHfZ_v31bfu0z2TB-JiZwhg0nWCigkohx7poGuhqyBttDONCmbLi2AnOJNaVqHJT6lJxhUyAMsCX5GHeTU-eJh3HtrdR6uMRB50ebPO6KUXyJVhC1zMqQ1IQtGl9sD2G35ZBe3bazk7bi9NUeJwLbvL_sX-mOnuP</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Jiang, Yina</creator><creator>Wu, Yinying</creator><creator>Zhang, Liwen</creator><creator>Wang, Yan</creator><creator>Xu, Guiping</creator><creator>Deng, Yuan</creator><creator>Han, Liang</creator><creator>Li, Enxiao</creator><creator>Ma, Qingyong</creator><creator>Xu, Mian</creator><creator>Wu, Zheng</creator><creator>Wang, Zheng</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20231201</creationdate><title>Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas</title><author>Jiang, Yina ; Wu, Yinying ; Zhang, Liwen ; Wang, Yan ; Xu, Guiping ; Deng, Yuan ; Han, Liang ; Li, Enxiao ; Ma, Qingyong ; Xu, Mian ; Wu, Zheng ; Wang, Zheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-f4ffafb717606da3a84990b8029eff137df563ab731ca86762f5e5d3da170df03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Yina</creatorcontrib><creatorcontrib>Wu, Yinying</creatorcontrib><creatorcontrib>Zhang, Liwen</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Xu, Guiping</creatorcontrib><creatorcontrib>Deng, Yuan</creatorcontrib><creatorcontrib>Han, Liang</creatorcontrib><creatorcontrib>Li, Enxiao</creatorcontrib><creatorcontrib>Ma, Qingyong</creatorcontrib><creatorcontrib>Xu, Mian</creatorcontrib><creatorcontrib>Wu, Zheng</creatorcontrib><creatorcontrib>Wang, Zheng</creatorcontrib><collection>Access via Oxford University Press (Open Access Collection)</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Precision clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Yina</au><au>Wu, Yinying</au><au>Zhang, Liwen</au><au>Wang, Yan</au><au>Xu, Guiping</au><au>Deng, Yuan</au><au>Han, Liang</au><au>Li, Enxiao</au><au>Ma, Qingyong</au><au>Xu, Mian</au><au>Wu, Zheng</au><au>Wang, Zheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas</atitle><jtitle>Precision clinical medicine</jtitle><date>2023-12-01</date><risdate>2023</risdate><volume>6</volume><issue>4</issue><spage>pbad030</spage><epage>pbad030</epage><pages>pbad030-pbad030</pages><issn>2096-5303</issn><eissn>2516-1571</eissn><abstract>Abstract Adenosquamous carcinoma of the pancreas (ASCP) is a rare histological subtype of pancreatic cancer with a poor prognosis and a high metastasis rate. However, little is known about its genomic landscape and prognostic biomarkers. A total of 48 ASCP specimens and 98 pancreatic ductal adenocarcinoma (PDAC) tumour specimens were sequenced to explore the genomic landscape and prognostic biomarkers. The homozygous deletion of the 9p21.3 region (including CDKN2A, CDKN2B, and MTAP) (9p21 loss) occurred in both ASCP and PDAC, and a higher frequency of 9p21 loss was observed in ASCP (12.5% vs 2.0%, P = 0.022). Notably, 9p21 loss was significantly associated with poor disease-free survival (DFS) in ASCP patients (mDFS (Median DFS) = 4.17 vs 7.33 months, HR (Hazard Ratio) = 3.70, P = 0.009). The most common gene alterations in patients with ASCP were KRAS (96%), TP53 (81%), CDKN2A (42%), SMAD4 (21%), CDKN2B (13%), and FAT3 (13%). The mutation rates of ACVR2A (6.25% vs 0%), FANCA (6.25% vs 0%), RBM10 (6.25% vs 0%), and SPTA1 (8.33% vs 1.02%) were significantly higher in ASCP than in PDAC. In conclusion, we have comprehensively described the genomic landscape of the largest cohort of ASCP patients to date and highlight that 9p21 loss may be a promising prognostic biomarker for ASCP, which provides a molecular basis for prognosis prediction and new therapeutic strategies for ASCP.</abstract><pub>Oxford University Press</pub><doi>10.1093/pcmedi/pbad030</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2096-5303
ispartof Precision clinical medicine, 2023-12, Vol.6 (4), p.pbad030-pbad030
issn 2096-5303
2516-1571
language eng
recordid cdi_proquest_miscellaneous_2895709371
source DOAJ Directory of Open Access Journals; Access via Oxford University Press (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central
title Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T16%3A41%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Loss%20of%20chromosome%209p21%20is%20associated%20with%20a%20poor%20prognosis%20in%20adenosquamous%20carcinoma%20of%20the%20pancreas&rft.jtitle=Precision%20clinical%20medicine&rft.au=Jiang,%20Yina&rft.date=2023-12-01&rft.volume=6&rft.issue=4&rft.spage=pbad030&rft.epage=pbad030&rft.pages=pbad030-pbad030&rft.issn=2096-5303&rft.eissn=2516-1571&rft_id=info:doi/10.1093/pcmedi/pbad030&rft_dat=%3Cproquest_cross%3E2895709371%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2895709371&rft_id=info:pmid/&rft_oup_id=10.1093/pcmedi/pbad030&rfr_iscdi=true